Zacks Investment Research downgraded shares of BIOTELEMETRY (BEAT) from N/A to NEUTRAL on August 23, 2013, with a target price of $8.60.
BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BIOTELEMETRY (BEAT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment